Presentation is loading. Please wait.

Presentation is loading. Please wait.

Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma) Altogen Biosystems offers the NTERA-2 Cell Transfection Reagent among a host of 100+ cell.

Similar presentations


Presentation on theme: "Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma) Altogen Biosystems offers the NTERA-2 Cell Transfection Reagent among a host of 100+ cell."— Presentation transcript:

1 Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma) Altogen Biosystems offers the NTERA-2 Cell Transfection Reagent among a host of 100+ cell line specific In Vitro Transfection Kits. The NTERA-2 Cell Transfection Reagent is a lipid mediated formulation, and it has been developed to provide high transfection efficiency with NTERA-2. This cell line is a good host for studying a range of areas within the field of biomedical therapeutics and biology. When cultured in vitro, NTERA-2 cells are a monolayer and adhere to the surface of the culture flask. Other applications include drug discovery, gene expression studies, molecular and cell biology research applications. Purchase NTERA-2 Transfection Kit at www.Altogen.com Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA Telephone  702 349 6103  Fax  702 989-0841  email  techserv@altogen.com

2 NTERA-2 Cell Line Description and Applications Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA Telephone  702 349 6103  Fax  702 989-0841  email  techserv@altogen.com NTERA-2 cells Wikipedia.org Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma) The NTERA-2 cell line originates from tissue taken after the xenograft of a Caucasian male patient 22 years of age. The patient suffered from a malignant pluripotent embryonic carcinoma of the testis, and as a result this cell line is an excellent tool in research related to certain types of testicular cancer. The NTERA-2 cell line was originally established in 1980 and displays a morphology similar to epithelial morphology. The cell line also has applications for research related to human neurogenesis because of the characteristics it shares with cells of an embryo. For example, NTERA-2 cells have a high nucleo-cytoplasmic ratio.

3 NTERA-2 Transfection Protocol 1. Plate 10,000 - 15,000 NTERA-2 cells per well in 0.5 ml of complete growth medium 12–24 hours prior to transfection 2. Wash with 1xPBS and add 0.5 ml of fresh growth medium 3. Prepare transfection complexes by mixing 40 µl of serum-free medium, 5.5 µl of transfection reagent, and 750 ng DNA (or mRNA), or 30 nM - 50 nM of siRNA (or microRNA) *Referred to a final volume including growth medium 4. Incubate transfection complexes at RT for 15 - 30 minutes 5. Optional: Add 2 µl of Complex Condenser. This reagent reduces the size of transfection complex, therefore increasing transfection efficiency; however it may increase cell toxicity 6. Add prepared transfection complexes to 0.5 ml of complete growth medium with NTERA-2 cells (from step 2) 7. Incubate cells at 37ºC in a humidified CO 2 incubator 8. Assay for phenotype or target gene expression 48 - 72 hours after transfection Optional: Transfection efficiency can be increased by addition of Transfection Enhancer reagent. Add 2 µl of Transfection Enhancer reagent 12-24 hours after transfection If the viability of NTERA-2 cells being transfected is affected at 16 - 24 hours post-transfection, the level of cytotoxicity can be decreased by changing the growth medium and eliminating redundant exposure of cells to transfectant Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA Telephone  702 349 6103  Fax  702 989-0841  email  techserv@altogen.com Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma)

4 General Lipoplex-mediated Transfection Mechanism of Action Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA Telephone  702 349 6103  Fax  702 989-0841  email  techserv@altogen.com Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma)

5 NTERA-2 Transfection Kit Product Details Two component formulation enhances lipid mediated transfection efficiency Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA Kit includes Transfection Enhancer reagent and recommended transfection protocol High transfection efficacy in the presence of serum Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid Reproducible transfection results Works well for standard reverse transfection and high-throughput applications Developed and manufactured by Altogen Biosystems (www.Altogen.com) Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA Telephone  702 349 6103  Fax  702 989-0841  email  techserv@altogen.com Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma)

6 Data Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into NTERA-2 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4). Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma)

7 Data Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Figure 2. Protein expression of Lamin A in NTERA-2 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into NTERA-2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control. Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma)

8 Pre-optimized transfection protocol for NTERA-2 cell line Compatible with DNA, small RNA (siRNA, shRNA, miRNA), mRNA, and small protein complexing Free of serum and protein of animal origin Compatible with standard and reverse transfection methods (both protocols provided in the kit manual) Easy to use NTERA-2 transfection protocol ensures great performance with expedited experimental timeline Equally efficient for single or multiple transfections Can be used for transient transfection and development of stable NTERA-2 cell lines Bio-degradable after endocytosis Used for preclinical research worldwide NTERA-2 Transfection Kit Benefits Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV  89107  USA Telephone  702 349 6103  Fax  702 989-0841  email  techserv@altogen.com Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma)


Download ppt "Products > NTERA-2 Transfection Reagent (Embryonal Carcinoma) Altogen Biosystems offers the NTERA-2 Cell Transfection Reagent among a host of 100+ cell."

Similar presentations


Ads by Google